68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients treated with First Full PRRT Abstract #1909

Introduction: Only few studies have correlated 18F-FDG and SSTR imaging with NET grade.
Aim(s): Compare 68Ga-DOTA-TOC and 18F-FDG-PET/CT in follow-up of NETs treated with PRRT.
Materials and methods: 66 patients with proven NET that underwent PRRT and 3 combined 68Ga-DOTA-TOC and 18F-FDG-PET/CT were evaluated. PET were performed before PRRT, 3 months after completion of PRRT and 6-9 months thereafter.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Prof.Dr. Margarida Rodrigues
Keywords: 68Ga-PET, FDG

To read results and conclusion, please login ...

Further abstracts you may be interested in

#851 Molecular Imaging of Somatostatin Receptors with 68Ga-DOTATOC-PET in Patients with Meningioma
Introduction: In vitro studies showed that meningioma cells may express somatostatin receptors (SSTRs), which bears the possibility of receptor-mediated radionuclide therapy in patients with meningioma.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Prof. Dr. Margarida Rodrigues
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#841 Quality of Life in Neuroendocrine Tumor Patients Compared to the General Population
Introduction: Literature on NET patients' quality of life (QOL) is scarce.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Eva M Gamper
Keywords: quality of life
#1309 Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET)
Introduction: 68Ga-DOTATATE (DOTA) and FDG PET have been utilised in NETs to aid diagnosis, prognostication and guide management. FDG PET avidity is associated with poor prognosis, but the prognostic significance of dual FDG/DOTA grading has not been explored.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr David Chan
Authors: Chan D, Bailey D, Schembri G, Bernard E, ...
Keywords: PET, prognosis
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini